Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension

Cindy Hutnik, David Neima, Fahim Ibrahim, Robert Scott, Julie Vaillancourt, Denis Haine, John S Sampalis, Natacha Bastien, Sylvain Foucart, Cindy Hutnik, David Neima, Fahim Ibrahim, Robert Scott, Julie Vaillancourt, Denis Haine, John S Sampalis, Natacha Bastien, Sylvain Foucart

Abstract

Purpose: To assess the effect of preservative-free dorzolamide-timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.

Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide-timolol formulation. The primary outcome was the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent changes in IOP from baseline to 4 and 8 weeks.

Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 (12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 (20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 4 weeks (P < 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P < 0.001), representing reductions of -38.5% (P < 0.001) and -38.0% (P < 0.001), respectively.

Conclusion: Preservative-free dorzolamide-timolol does not increase eye discomfort while significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension.

Keywords: GSS-SYMP-6; dorzolamide–timolol; intraocular pressure; ocular hypertension; open-angle glaucoma; preservative-free.

Figures

Figure 1
Figure 1
Percent change in intraocular pressure (IOP) of the worse eye between week 4 and baseline.
Figure 2
Figure 2
Percent change in intraocular pressure (IOP) of the worse eye between week 8 and baseline.
Figure 3
Figure 3
Patients’ and ophthalmologists’ global satisfaction with 8 weeks preservative-free dorzolamide–timolol treatment.

References

    1. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090–1095.
    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82(11):844–852.
    1. Adatia FA, Damji KF. Chronic open-angle glaucoma. Review for primary care physicians. Can Fam Physician. 2005;51:1229–1237.
    1. Lee AG, Beaver HA. Visual loss in the elderly – Part I: Chronic visual loss: what to recognize and when to refer. Clin Geriatr. 2003;11(6):46–53.
    1. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging. 2005;22(4):315–321.
    1. Damji KF, Behki R, Wang L. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Target IOP workshop participants. Can J Ophthalmol. 2003;38(3):189–197.
    1. Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drug Aging. 2006;23(12):977–995.
    1. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945–1951.
    1. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832–833.
    1. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105(10):1952–1959.
    1. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2% timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82(1):42–48.
    1. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005;21(3):242–249.
    1. Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS. Comparing the fixed combination dorzolamide-timolol (COSOPT) to concomitant administration of 2% dorzolamide (trusopt) and 0.5% timolol – a randomized controlled trial and a replacement study. COSOPT Study Group. J Clin Pharm Ther. 2004;29(4):375–380.
    1. Gandolfi SA, Rossetti L, Cimino L, Mora P, Tardini M, Orzalesi N. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. J Glaucoma. 2003;12(4):347–353.
    1. Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mmHg. J Glaucoma. 2005;14(4):267–270.
    1. Hutzelmann J, Owens S, Shedden A, Adamson I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82(11):1249–1253.
    1. Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology. 2008;115(1):99–103.
    1. Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. Eye. 2008;22(9):1172–1179.
    1. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma. 2004;13(2):168–173.
    1. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423.
    1. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349.
    1. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
    1. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–1268.
    1. Lee BL, Gutierrez P, Gordon M, et al. The glaucoma symptom scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116(7):861–866.
    1. Canadian Ophthalmological Society Evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44(Suppl 1):S7–S93.
    1. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716–726.
    1. Chawla A, McGalliard JN, Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85(4):464.
    1. Beckers HJ, Schouten JS, Webers CA, van der Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1485–1490.
    1. American Academy of Ophthalmology . Preferred practice pattern: primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2005. Available from: (Accessed October 07, 2009).
    1. European Glaucoma Society . Terminology and Guidelines for Glaucoma. 2nd ed. Savona, Italy: The Society; 2003. Available from: (accessed October 07, 2009)
    1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
    1. Martinez A, Sánchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clin Ther. 2008;30(6):1120–1134.
    1. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117–1122.
    1. Webers CA, van der Valk R, Schouten JS, Zeegers MP, Prins MH, Hendrikse F. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology. 2007;114(1):40–46.
    1. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001;22(1):8–18.
    1. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Cornea. 1998;17(6):574–583.
    1. Pasquale LR, Kang JH. Lifestyle, nutrition, and glaucoma. J Glaucoma. 2009;18(6):423–428.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir